Bladder urothelial carcinoma (BUC) shows significant molecular heterogeneity across populations. This systematic review analyzed Asian patient data from cBioPortal, GENIE, and PubMed (inception–July 2024) to characterize FGFR3 genomic alterations. Across datasets, at least 14.6% (average 18.4%) of patients exhibited FGFR3 mutations or structural variants, with the S249C mutation being the most common. These alterations were largely mutually exclusive with TP53 mutations, indicating distinct tumorigenic pathways. Given the therapeutic relevance of FGFR3—including the availability of the FDA-approved FGFR inhibitor erdafitinib—routine molecular profiling may enhance treatment selection and improve outcomes for Asian BUC patients.

To Be Updated.